1,869 results on '"Freeman, Gordon J."'
Search Results
2. Regulation of HHLA2 expression in kidney cancer and myeloid cells
3. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
4. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
5. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity
6. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
7. PI3Kβ controls immune evasion in PTEN-deficient breast tumours
8. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy
9. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model
10. The B7:CD28 family and friends: Unraveling coinhibitory interactions
11. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
12. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
13. The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018
14. High‐fidelity detection and sorting of nanoscale vesicles in viral disease and cancer
15. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
16. Blockade of RGMb inhibits allergen-induced airways disease
17. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
18. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells
19. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
20. Publisher Correction: Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
21. Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
22. Figure S6 from PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
23. Data from PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
24. Supplementary Methods 1 from PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
25. Supplementary Tables 1-6 from PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
26. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
27. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
28. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
29. mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection
30. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
31. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
32. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model
33. Supplementary Figure 6 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
34. Supplementary Figure 9 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
35. Supplementary Figure 13 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
36. Supplementary Figure 5 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
37. Supplementary Figure 3 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
38. Supplementary Figure 7 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
39. Supplementary Figure 2 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
40. Supplementary Figure 4 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
41. Data from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
42. Supplementary Figure 8 from Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
43. PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
44. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
45. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
46. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
47. The importance of exosomal PDL1 in tumour immune evasion
48. Acidity changes immunology: a new VISTA pathway
49. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
50. Inclusion of CD80 in HSV Targets the Recombinant Virus to PD-L1 on DCs and Allows Productive Infection and Robust Immune Responses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.